Latest News

Plant Advanced Technologies SA saw lower sales but slightly higher revenue in 2024 compared to the previous year.

The European medical cannabis and industrial hemp group SYNBIOTIC SE and the venture capital company IRIS Capital Investment have entered into a strategic partnership.

Oncodesign Precision Medicine has set up a new equity financing line of up to €5 million with IRIS to strengthen its cash position and support the development of its clinical programs amid challenging market conditions.

CARMAT announces a flexible 24-month equity financing line with IRIS, allowing the issuance of up to 9 million shares—around 15% of its current capital.

Median Technologies secures up to €10 million in fresh funding from IRIS, underscoring IRIS’s pivotal role in accelerating the company’s AI-driven cancer diagnostics.

Theranexus strikes a major milestone as IRIS steps in with a strategic licensing and distribution deal to propel TX01 toward global commercialization in rare neurological diseases.

French expert in electric micro-mobility, announces the establishment of financing for a maximum total amount of 2 million euros

​

Sumitomo Pharma and Poxel reported that a post-marketing study of TWYMEEG® in Japanese type 2 diabetes patients with renal impairment showed a safety profile consistent with previous trials, supporting plans to discuss updating the drug’s label with regulators in 2024.

Kalray reported stable H1 2024 revenue, confirmed strong expected growth driven by a major €100 M contract and a planned merger with Pliops, and strengthened its financing to support expansion in AI data acceleration.

Theranexus announced regulatory alignment with the FDA and EMA on efficacy endpoints for Batten-1 and optimized its upcoming Phase III trial—focused on visual acuity in younger patients—while securing new financing to prepare for its launch.

Temisis completed the first phase of a new capital increase, led by SFHBB, to fund clinical development of its promising psoriasis drug candidate.

Plant Advanced Technologies PAT has set up a flexible €1 million equity financing line with Iris to strengthen its financial structure and support future growth projects

TheraVet has secured a flexible €3 million equity-linked financing facility with IRIS to support its operations and funding needs through early 2026.

Theranexus raised €3.1 million to fund the Phase 3 development of Batten-1, with strong investor demand and BBDF becoming an 11.6% shareholder.

ABIONYX Pharma is launching a new GMP biomanufacturing campaign for its ApoA-I therapy, financed by an equity-linked facility of up to €12 million subscribed by IRIS.

Poxel extended its cash runway to Q2 2025 via debt restructuring and new financing, supported by rising TWYMEEG® sales and clinical progress.

Cerinnov Group set up a flexible equity-linked financing line of up to €2 million with IRIS—starting with a €200 k first draw—to reinforce its cash position ahead of an expected post-pandemic rebound.

Poxel extended its cash runway to at least February 2023 through debt restructuring and a new €6 million equity-linked financing with IRIS.

Spexis extended its cash runway into January 2023, refocused resources on its Phase 3 ColiFin® program, and renewed a CHF 15 million equity-linked financing with IRIS.

Magnum secured a $20 million funding facility from IRIS, starting with a $1.3 million tranche to advance its Green Pig Iron project and complete the bankable feasibility study.

Energisme set up a flexible 24-month equity financing line of up to €10 million with IRIS, drawing an initial €600,000 to support its next growth phase.

Theranexus reported €12.5 M in cash at end-2021 and set up a new 12-month, €4.2 M equity-linked financing line with IRIS to support its clinical programs, including BBDF-101.

CIBOX set up a €1.5 million equity-linked financing line with IRIS to accelerate its expansion in electric mobility, starting with three tranches of €500,000 each.

Hybrigenics set up a highly flexible €50 million, 24-month equity-linked financing line with IRIS, starting with a €1.5 million first draw, to fund targeted investments in innovative personalized-medicine technologies.

BOOSTHEAT set up a flexible €10 million equity-linked financing line with IRIS to cover its 12-month funding needs and support the launch of its BOOSTHEAT.20 CONNECT boiler.

Theranexus reported ongoing progress on its THN102 and BBDF-101 programs, €11.2m in cash at 31 December 2020, and the implementation of a new €8.4m equity line with IRIS to extend its funding visibility and support BBDF-101 development.

Polyphor set up a two-year, CHF 19.3 million equity-linked financing line with IRIS to ensure flexible funding for the continued development of balixafortide and its oncology/antibiotics pipeline.

Theranexus reported €13.3 M pro forma cash at 30 June 2020 and set up a flexible €4.2 M mandatory convertible bond facility with IRIS to support its growth, notably the BBDF-101 program.

Bone Therapeutics secured €11 million in mixed financing—including bridge loans, equity, and a flexible convertible bond facility—to advance its late-stage ALLOB and JTA-004 programs through upcoming clinical milestones.

Santhera set up a flexible equity-linked financing line of up to CHF 12 million—extendable to CHF 24 million—to reinforce liquidity for its regulatory and development programs, with monthly discounted share issuances to IRIS.

DMS Group set up a €4 million financing through IRIS via warrants convertible into cash and/or DMS or Hybrigenics shares to support its strong growth and working capital needs.